CD274 and breast cancer: By employing the MB49 BC model and performing serial in vivo and in vitro passaging while using an anti-PD-L1 antibody, anti-PD-L1-resistant MB49 cell lines were derived after seven cycles of passaging, displaying unresponsiveness to anti-PD-L1 treatment in vivo (Fig. 1J, K).